Molecular docking studies of potent and selective orally bioavailable dihydro-pyrazole Gpr-40 agonists as Alpha-Glucosidase Inhibitors (AGIS)
Shri RLT Institute of Pharmaceutical Science and Technology, Ekdil, Etawah, Uttar Pradesh, India.
Research Article
World Journal of Biology Pharmacy and Health Sciences, 2023, 13(03), 094–100.
Article DOI: 10.30574/wjbphs.2023.13.3.0117
Publication history:
Received on 26 January 2023; revised on 10 March 2023; accepted on 13 March 2023
Abstract:
The primary goal of this study is to bring the elevated blood sugars down to a normal range, both to improve symptoms of diabetes as well as to prevent or delay diabetic complications. Achieving this goal requires a comprehensive, coordinated, patient-centered approach on the part of the healthcare system. The potions extracted from the generated Docking models are statistically aesthetic and provide enough assumptions about the character as well as the nature of substitutions favourable to boost the biological efficiency of novel analogous. The potion provided by these computational studies helps to derive an impactful path to design more potent antihyperglycemic counterparts of dihydro-pyrazole.
Keywords:
Diabetes; Molecular docking; Dihydro-pyrazole; Insulin
Full text article in PDF:
Copyright information:
Copyright © 2023 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0